drugset / Trial / NCT06749691
Liposomal Irinotecan and Apatinib in ES-SCLC
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to observe the efficacy and safety of liposomal irinotecan combined with apatinib in the treatment of extensive stage small cell lung cancer progressed from first-line regimen.
Timeline
- Start
- 2024-12-28
- Primary completion
- 2027-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | — | — |
| Subject | Rivoceranib | Small molecule | — | — |